Premium
Development of CMV Antibody Tests and Their Clinical Evaluation
Author(s) -
Wielaard F.,
Scherders J.,
Dagelinckx C.,
Hooijmans A.,
SmitSiebinga C. T.,
Welle F.
Publication year - 1986
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1986.tb01991.x
Subject(s) - seroconversion , antibody , medicine , immunology , antigen , monoclonal antibody , virology , population , screening test , pediatrics , environmental health
. An anti‐CMV ELISA was developed in which monoclonal antibodies to immobilize the CMV antigens are used. The test was compared with the IHA test and there was 98.6% agreement. Using the CF test as a referee, sensitivity and specificity of the ELISA were calculated to be 98.6 and 99.0%, respectively. The seroconversion rate among Dutch donors was estimated from the age‐related prevalence of anti‐CMV antibodies to be about 0.4%. Specific anti‐CMV IgM was searched for in a large donor population using an antibody‐capture IgM ELISA; 1 of 600 donor sera was found positive. This makes it unlikely that screening for IgM anti‐CMV will effectively prevent posttransfusion CMV infections. In order to meet the demand for simpler tests, a one‐step ELISA was recently developed, based on the inhibition principle. Preliminary studies with this test indicate a high sensitivity and specificity.